Eton Pharmaceuticals, Inc.
ETON
$58.83
-$0.52-0.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 98.59% | 40.41% | 82.72% | 117.54% | 108.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 98.59% | 40.41% | 82.72% | 117.54% | 108.60% |
| Cost of Revenue | 98.83% | 46.22% | 30.73% | 230.18% | 68.13% |
| Gross Profit | 98.48% | 37.10% | 124.23% | 45.65% | 133.40% |
| SG&A Expenses | 20.02% | 13.91% | 31.29% | 53.29% | 73.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.78% | 29.45% | 58.59% | 129.22% | 59.85% |
| Operating Income | 5,116.42% | 311.31% | 327.78% | -107.66% | 90.87% |
| Income Before Tax | 565.18% | 205.07% | 376.71% | -490.22% | 15.67% |
| Income Tax Expenses | 112.12% | -72.97% | -179.31% | 77.78% | 22.22% |
| Earnings from Continuing Operations | 547.89% | 198.85% | 347.99% | -407.34% | 15.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 547.89% | 198.85% | 347.99% | -407.34% | 15.00% |
| EBIT | 5,116.42% | 311.31% | 327.78% | -107.66% | 90.87% |
| EBITDA | 1,912.21% | 131.16% | 291.92% | 23.25% | 127.75% |
| EPS Basic | 535.90% | 197.44% | 340.61% | -396.28% | 18.56% |
| Normalized Basic EPS | 1,016.72% | 631.33% | 3,547.83% | -221.49% | 57.87% |
| EPS Diluted | 450.00% | 183.33% | 282.37% | -458.50% | 16.67% |
| Normalized Diluted EPS | 873.11% | 559.04% | 3,069.57% | -224.58% | 57.87% |
| Average Basic Shares Outstanding | 2.79% | 1.48% | 3.06% | 3.83% | 4.33% |
| Average Diluted Shares Outstanding | 21.92% | 17.34% | 19.54% | 1.29% | 4.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |